Moleculin Biotech is trading 6.4% lower at $0.56 in after-hours trading; no clear company-specific catalyst for the decline was identified.
- Shares closed at $0.60 on September 25, despite a 6.12% regular-session gain.
- On September 25, the company announced preclinical Annamycin data in pancreatic cancer describing a potential immune-mediated effect; the findings do not establish a cause for the after-hours decline.
- Recent daily moves included a 32.71% drop on September 21 and gains on September 24 and 25.